Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

M6620 and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery


This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Davis, Elizabeth

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: